Business Description
Fulcrum Therapeutics is a US-based clinical-stage company focused on developing targeted treatments for patients with serious genetic diseases that currently have few or no effective options. Its lead drug candidate, pociredir, works by stimulating the production of fetal hemoglobin and is being tested as a potential treatment for sickle cell disease and beta-thalassemia. The company is also researching treatments for other rare blood and fibrotic conditions, and holds a licensing agreement with CAMP4 covering key compounds and related intellectual property. Founded in 2015 and based in Cambridge, Massachusetts, Fulcrum is working to turn genetic insights into meaningful therapies for underserved patient populations.
